Hytacand (Hydrochlorothiazide, Candesartan Cilexetil)

Candesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide reduces sodium and chloride reabsorption in the distal tubule, increasing urine output and decreasing plasma volume. Together they lower vascular resistance and blood volume, reducing blood pressure.

The specific dose of Hytacand is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health. Dosage adjustments are made individually; patients should follow the prescriber’s instructions.

The safety of Hytacand in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Hytacand, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with single‑agent therapy, the fixed‑dose combination of candesartan and hydrochlorothiazide offers complementary mechanisms, often achieving better blood‑pressure control with a single tablet. This can improve adherence versus taking two separate medications.

Store Hytacand at ambient temperature, below 25 °C, in the original packaging. Keep the tablets away from moisture, heat, and direct sunlight to maintain stability.

Hytacand is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances (especially low potassium), acute kidney injury, hyperkalemia, and rare cases of angioedema. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing.

Hytacand is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, or a history of angioedema related to ARB therapy. It should also be avoided in patients taking certain potassium‑sparing agents without close monitoring.